The antibody contract manufacturing market is growing at an annualized rate of 12%, claims Roots Analysis

kevin987

154
views

Although biopharmaceuticals offer significant profit margins and have been proven to be effective in treating a myriad of diseases

With over100 therapeutic monoclonal antibodies and antibody-based products in themarket, the demand for developing and manufacturing of such products isanticipated to increase beyond the capabilities of innovator companies alone

Roots Analysis has announced the addition of the “Antibody ContractManufacturing Market, 2020-2030” report to its listof offerings.

Althoughbiopharmaceuticals offer significant profit margins and have been proven to beeffective in treating a myriad of diseases, they are generally associated withhigh costs of development and complex manufacturing protocols; this is true forantibody-based products as well. Presently, there are a number of companiesthat claim to offer end-to-end solutions, ranging from antibody development tocommercial production. Further, prevalent trends suggest that sponsor companiesare likely to continue relying on contract service providers for variousaspects of antibody-based product development and manufacturing.

To order this 285+ page report, which features 100+ figuresand 110+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html

Key Market Insights

Over 100 CMOspresently claim to offer manufacturing services for antibodies

The antibody contractmanufacturing market is currently dominated by the presence of small andmid-sized companies, which represent 70% of the industry stakeholders. It isalso worth highlighting that more than 55% of CMOs claim to have thecapabilities to manufacture antibodies across all scales of operation(preclinical, clinical and commercial).

More than 90% service providers are focused on theproduction of monoclonal antibodies

However, playersbased in Asia are now increasingly focusing on the development of bispecificantibodies for therapeutic use. It worth highlighting that close to 20% of theCMOs engaged in this domain claim to offer manufacturing services for bothbispecific antibodies and antibody fragments.

Europe has emerged as a key manufacturing hub forantibody-based products

More than 120manufacturing facilities have been established by various players, worldwide;of these, 40% are in Europe. Additionally, 40% of the total installed capacityis in Europe, followed by Asia. Some of the prominent regions in Asia include (indecreasing order of number of manufacturing facilities) China, South Korea,India, Japan and Taiwan.

More than 90 partnershipagreements have been inked between 2013 and 2019

Majority of theseagreements were focused on manufacturing of various types of antibodies. Otherpopular types of collaboration models include process development andmanufacturing agreements (22%), product development and manufacturingagreements (10%) and licensing agreements (7%).

Multiple expansioninitiatives were undertaken by CMOs between 2017 and 2019

More than 50% of suchinitiatives were reported to be focused on the expansion of manufacturing facilities,followed by building new facilities (38%). It is worth noting that close to 50%of the total number of expansion initiatives were undertaken in Europe, ofwhich, 25% were in the UK.

Demand fortherapeutic antibodies is anticipated to grow at a CAGR of 10%, during2020-2025

Given the fact thatthere are a number of antibody-based products in the market, the commercialdemand for antibodies is significantly higher than the clinical demand. Acrossthe three major global regions, North America represent over half of theoverall global manufacturing demand for antibodies.

North America andEurope are anticipated to capture over 70% of the market share by 2030

However, the marketin the Asia is anticipated to grow at a relatively faster rate. Further,presently, more than 90% of the antibodies are being developed using mammalianexpression systems, and this trend is unlikely to change significantly in shortto mid-term.

To request a sample report - https://www.rootsanalysis.com/reports/295/request-sample.html

KeyQuestions Answered

§ Who are the leading CMOs engaged in the production ofantibody-based therapeutics?

§ What kind of partnership models are commonly adopted bystakeholders in this industry?

§ What is the annual clinical and commercial demand for antibody-basedproducts?

§ What is the current installed capacity for manufacturing ofantibodies?

§ What are the various expansion initiatives undertaken byantibody CMOs?

§ How is the current and future market opportunity likely tobe distributed across key market segments?

The USD 17 billion (by 2030) financial opportunitywithin the antibody contract manufacturing market has been analyzed across thefollowing segments:

§ Typeof Antibodies

§ MonoclonalAntibodies

§ BispecificAntibodies

§ ADCs

§ Others

§ Company Size

§ Small

§ Mid-sized

§ Large / Very Large

§ Scaleof Operation

§ Preclinical / Clinical

§ Commercial

§ Typeof expression system used

§ Mammalian

§ Microbial

§ Keygeographical regions

§ NorthAmerica

§ Europe

§ Asiaand RoW

The report featuresinputs from eminent industry stakeholders, according to whom antibodytherapeutics developers are increasingly outsourcing their manufacturing operationsowing to complex nature of the overall process, as well as the high investmentsassociated with setting-up in-house expertise. The report includes detailedtranscripts of discussions held with the following experts:

§ Dietmar Katinger (Chief Executive Officer, PolymunScientific)

§ David C Cunningham (Director, Corporate Development,Goodwin Biotechnology)

§ Claire Otjes (Marketing Manager, Batavia Biosciences)

The research coversprofiles of key players that offer manufacturing services for antibodies,featuring a company overview, information on their respective serviceportfolios, manufacturing facilities and capabilities, and an informed futureoutlook.

§ AGC Biologics

§ Aldevron

§ AMRI

§ Boehringer Ingelheim BioXcellence

§ Emergent BioSolutions

§ Eurofins CDMO

§ FUJIFILM Diosynth Biotechnologies

§ KBI Biopharma

§ Lonza

§ Nitto Avecia Pharma Services

§ Novasep

§ Pierre Fabre